Selected research
Industry Research
Solid Tumor Drug Industry Research Report 2026
Market perspective
The global Solid Tumor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Solid Tumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Solid Tumor Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Solid Tumor Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Solid Tumor Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Solid Tumor Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Solid Tumor Drug Market by Company
Johnson & Johnson
Pfizer Inc
GlaxoSmithKline plc.
Baxter
AstraZeneca
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Celgene Corporation
Bristol-Myers Squibb Company
Biogen
Amgen Limited & Amgen Ireland Limited
Abbott Laboratories
Solid Tumor Drug Segment by Type
Small Molecules
Biologics
Solid Tumor Drug Segment by Application
Radiology
Neurology
Oncology
Others
Solid Tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Solid Tumor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecules
- Biologics
Applications
- Radiology
- Neurology
- Oncology
- Others
Companies covered
- Johnson & Johnson
- Pfizer Inc
- GlaxoSmithKline plc.
- Baxter
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Celgene Corporation
- Bristol-Myers Squibb Company
- Biogen
- Amgen Limited & Amgen Ireland Limited
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Solid Tumor Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecules
- 2.2.3 Biologics
- 2.3 Solid Tumor Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Radiology
- 2.3.3 Neurology
- 2.3.4 Oncology
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Solid Tumor Drug Breakdown Data by Type
- 3.1 Global Solid Tumor Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Solid Tumor Drug Forecasted Market Size by Type (2027-2032)
4 Solid Tumor Drug Breakdown Data by Application
- 4.1 Global Solid Tumor Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Solid Tumor Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Solid Tumor Drug Market Perspective (2021-2032)
- 5.2 Global Solid Tumor Drug Growth Trends by Region
- 5.2.1 Global Solid Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Solid Tumor Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Solid Tumor Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Solid Tumor Drug Market Dynamics
- 5.3.1 Solid Tumor Drug Industry Trends
- 5.3.2 Solid Tumor Drug Market Drivers
- 5.3.3 Solid Tumor Drug Market Challenges
- 5.3.4 Solid Tumor Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Solid Tumor Drug Players by Revenue
- 6.1.1 Global Top Solid Tumor Drug Players by Revenue (2021-2026)
- 6.1.2 Global Solid Tumor Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Solid Tumor Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Solid Tumor Drug Head Office and Area Served
- 6.4 Global Solid Tumor Drug Players, Product Type & Application
- 6.5 Global Solid Tumor Drug Manufacturers Established Date
- 6.6 Global Solid Tumor Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Solid Tumor Drug Market Size (2021-2032)
- 7.2 North America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Solid Tumor Drug Market Size by Country (2021-2026)
- 7.4 North America Solid Tumor Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Solid Tumor Drug Market Size (2021-2032)
- 8.2 Europe Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Solid Tumor Drug Market Size by Country (2021-2026)
- 8.4 Europe Solid Tumor Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Solid Tumor Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Solid Tumor Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Solid Tumor Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Solid Tumor Drug Market Size (2021-2032)
- 10.2 South America Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Solid Tumor Drug Market Size by Country (2021-2026)
- 10.4 South America Solid Tumor Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Solid Tumor Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Solid Tumor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Solid Tumor Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Solid Tumor Drug Business (2021-2026)
- 12.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Pfizer Inc
- 12.2.1 Pfizer Inc Company Information
- 12.2.2 Pfizer Inc Business Overview
- 12.2.3 Pfizer Inc Revenue in Solid Tumor Drug Business (2021-2026)
- 12.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
- 12.2.5 Pfizer Inc Recent Developments
- 12.3 GlaxoSmithKline plc.
- 12.3.1 GlaxoSmithKline plc. Company Information
- 12.3.2 GlaxoSmithKline plc. Business Overview
- 12.3.3 GlaxoSmithKline plc. Revenue in Solid Tumor Drug Business (2021-2026)
- 12.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
- 12.3.5 GlaxoSmithKline plc. Recent Developments
- 12.4 Baxter
- 12.4.1 Baxter Company Information
- 12.4.2 Baxter Business Overview
- 12.4.3 Baxter Revenue in Solid Tumor Drug Business (2021-2026)
- 12.4.4 Baxter Solid Tumor Drug Product Portfolio
- 12.4.5 Baxter Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Solid Tumor Drug Business (2021-2026)
- 12.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 F. Hoffmann-La Roche Ltd.
- 12.6.1 F. Hoffmann-La Roche Ltd. Company Information
- 12.6.2 F. Hoffmann-La Roche Ltd. Business Overview
- 12.6.3 F. Hoffmann-La Roche Ltd. Revenue in Solid Tumor Drug Business (2021-2026)
- 12.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
- 12.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 12.7 Eli Lilly and Company
- 12.7.1 Eli Lilly and Company Company Information
- 12.7.2 Eli Lilly and Company Business Overview
- 12.7.3 Eli Lilly and Company Revenue in Solid Tumor Drug Business (2021-2026)
- 12.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
- 12.7.5 Eli Lilly and Company Recent Developments
- 12.8 Celgene Corporation
- 12.8.1 Celgene Corporation Company Information
- 12.8.2 Celgene Corporation Business Overview
- 12.8.3 Celgene Corporation Revenue in Solid Tumor Drug Business (2021-2026)
- 12.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
- 12.8.5 Celgene Corporation Recent Developments
- 12.9 Bristol-Myers Squibb Company
- 12.9.1 Bristol-Myers Squibb Company Company Information
- 12.9.2 Bristol-Myers Squibb Company Business Overview
- 12.9.3 Bristol-Myers Squibb Company Revenue in Solid Tumor Drug Business (2021-2026)
- 12.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
- 12.9.5 Bristol-Myers Squibb Company Recent Developments
- 12.10 Biogen
- 12.10.1 Biogen Company Information
- 12.10.2 Biogen Business Overview
- 12.10.3 Biogen Revenue in Solid Tumor Drug Business (2021-2026)
- 12.10.4 Biogen Solid Tumor Drug Product Portfolio
- 12.10.5 Biogen Recent Developments
- 12.11 Amgen Limited & Amgen Ireland Limited
- 12.11.1 Amgen Limited & Amgen Ireland Limited Company Information
- 12.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
- 12.11.3 Amgen Limited & Amgen Ireland Limited Revenue in Solid Tumor Drug Business (2021-2026)
- 12.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
- 12.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
- 12.12 Abbott Laboratories
- 12.12.1 Abbott Laboratories Company Information
- 12.12.2 Abbott Laboratories Business Overview
- 12.12.3 Abbott Laboratories Revenue in Solid Tumor Drug Business (2021-2026)
- 12.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
- 12.12.5 Abbott Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst